One company that is capturing the attention of investors on Wall Street is NanoViricides. Located in West Haven, Connecticut, NanoViricides is a development stage company that has quickly evolved into a leader in the fight against such viral diseases as H1N1, Swine flu, HIV and Herpes. Today, NanoViricides announced trademark registration for their mark “nanoviricides.”

The mark “nanoviricides” consists of standard characters without claim to any particular font, style, size, or color. The mark is now a registered trademark under the US Patents and Trademarks Office (USPTO) and was entered into the “principal register” of trademarks on April 20, 2010.

A nanoviricide is created chemically attaching a “ligand” to a base TheraCour nanomicelle. The ligand is a special chemical entity that is designed to bind to a virus particle. The specificity of a nanoviricide is expected to be determined by the specificity of the ligand.

The young company created the word “nanoviricide” in 2005 and defined it to describe a specific type of antiviral nanomaterial that is designed to destroy and fight against virus particles.

NanoViricides believes their trademark antiviral material is designed to “fool” a deadly virus into thinking it is entering into a host cell while in fact the virus would be binding to and becoming entrapped inside a nanoviricide micelle which would bring relief to patients fighting such issues.

Currently, NanoViricides is trading in the $2.06 range. With their new trademark and a worthy fight against viruses, NanoViricides is a company to keep an eye on. To learn more about this up-and-coming company, visit their website at: www.nanoviricides.com.